Adamas Pharma (ADMS) Prices 12.5M Share Follow-On Offering at $4.40/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/30/2026
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
- Equity positioning stays overweight, but summer extremes have eased: Barclays
- Oil prices rise by about $1/bbl on stalled US-Iran talks and tight fuel markets
- Micron reports Q4 today: Why Lynx Equity sees massive upside
- Moderna: Citi says oncology optimism is priced in, cuts rating to sell
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- Zimbabwe helicopter crash kills six, government spokesperson says
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
Adamas Pharma (ADMS) Announces Launch of Follow-on Public Offering
February 24, 2021 4:09 PM ESTAdamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that it has commenced an underwritten public offering of its common stock. All shares of... More
Adamas Pharma (ADMS) Misses Q4 EPS by 13c
February 23, 2021 4:56 PM ESTAdamas Pharma (NASDAQ: ADMS) reported Q4 EPS of ($0.64), $0.13 worse than the analyst estimate of ($0.51). Revenue for the quarter came in at $21 million versus the consensus estimate of $20.96 million.
As of December 31, 2020, Adamas had $83.4 million of cash, cash equivalents and available-for-sale securities. Subsequent to December 31, 2020,... More
